Helus Pharma, the commercial operating name of Cybin Inc., provided updates on its lead drug candidates, HLP003 and HLP004, during an investor presentation held on October 21, 2026. The company reaffirmed that topline results from its APPROACH Phase 3 study of HLP003 as an adjunctive treatment for major depressive disorder (MDD) remain on track for the fourth quarter of 2026. Enrollment of 223 participants in APPROACH was completed in July, while enrollment continues in EMBRACE, the second pivotal Phase 3 study. HLP003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA), and Helus Pharma expects to submit a New Drug Application in 2028. The company also outlined plans to initiate a Phase 2 study of HLP004 as a potential monotherapy for generalized anxiety disorder (GAD) in the first quarter of 2027. The randomized, double-blind, placebo-controlled study is expected to enroll approximately 144 adults to evaluate two 30 mg administrations of HLP004 against placebo, with primary and key secondary efficacy assessments at weeks six and 12, respectively.
These developments matter because they represent a significant step forward in the clinical validation of novel serotonergic agonists (NSAs) for mental health conditions. HLP003's Breakthrough Therapy Designation from the FDA underscores the potential of this treatment to address the large unmet need in depression, where existing therapies often fail to provide adequate relief. The completion of enrollment in the first Phase 3 trial and the progress of the second pivotal study signal that Helus Pharma is moving closer to regulatory submission, with an NDA planned for 2028. For the psychedelics industry, this is a critical milestone: it demonstrates that rigorously designed late-stage trials for psychedelic-inspired compounds are feasible and can attract regulatory attention. The advancement of HLP004 into Phase 2 for GAD further expands the potential market for NSAs, offering a new mechanism of action for anxiety disorders that have seen limited innovation in recent decades.
Helus Pharma is a clinical-stage pharmaceutical company founded in 2019, committed to helping minds heal by developing proprietary NSAs—synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. The company operates in Canada, the United States, the United Kingdom, and Ireland. Its lead candidate, HLP003, is in Phase 3 development for the adjunctive treatment of MDD, while HLP004 is in Phase 2 for GAD. The company's extensive research portfolio of investigational NSAs positions it as a key player in the evolving mental health therapeutics landscape.
For investors and industry observers, the timeline is clear: topline data for HLP003 is expected in the fourth quarter of 2026, and the Phase 2 study for HLP004 will begin in the first quarter of 2027. These catalysts could significantly impact Helus Pharma's valuation and the broader psychedelics sector. PsychedelicNewsWire, a specialized communications platform focused on all aspects of psychedelics, is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries. The platform also offers article and editorial syndication to 5,000+ outlets, enhanced press release enhancement to ensure maximum impact, and social media distribution via IBN to millions of social media followers. With broad reach and a seasoned team of contributing journalists and writers, PNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public.
For more information about Helus Pharma, visit www.helus.com. The latest news and updates relating to HELP are available in the company's newsroom. PsychedelicNewsWire is where breaking news, insightful content and actionable information converge.
